Aerpio Pharmaceuticals is a biopharmaceutical company focused on advancing first-in-class treatments for ocular disease. Aerpioâs lead product candidate, AKB-9778, a small molecule activator of the Tie-2 pathway, is being developed for the treatment of non-proliferative diabetic retinopathy. In contrast to marketed treatments for non-proliferative diabetic retinopathy that are administered by a physician via intraocular injection, AKB-9778 is delivered systemically by self-administered subcutaneous injection. We believe this delivery method provides an opportunity to treat patients at an earlier stage of disease, potentially reducing the likelihood of these patients developing vision-threatening complications. Source
No articles found.
We are an innovative clinical-stage biopharmaceutical company primarily focused on...
We are an innovative clinical-stage biopharmace...
Natureâs Sunshine Products (NASDAQ:NATR), a leading natural health and wellness ...
Natureâs Sunshine Products (NASDAQ:NATR), a l...
BioSig Technologies is a medical device company developing a proprietary technolog...
BioSig Technologies is a medical device company...
As a leading manufacturer of medical devices and components, Atrion makes a wide r...
As a leading manufacturer of medical devices an...
PAVmed Inc. is a highly differentiated, multiproduct medical device company employ...
PAVmed Inc. is a highly differentiated, multipr...
STAAR, which has been dedicated solely to ophthalmic surgery for over 30 years, de...
STAAR, which has been dedicated solely to ophth...
Acceleron is dedicated to the discovery and development of innovative, life-changi...
Acceleron is dedicated to the discovery and dev...
Join the National Investor Network and get the latest information with your interests in mind.